[Federal Register Volume 83, Number 185 (Monday, September 24, 2018)]
[Notices]
[Pages 48319-48320]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-20664]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Yogikala Prabhu, Ph.D., 301-761-7789; 
[email protected]. Licensing information and copies of the patent 
applications listed below may be obtained by communicating with the 
indicated licensing contact at the Technology Transfer and Intellectual 
Property Office, National Institute of Allergy and Infectious Diseases, 
5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed 
Confidential Disclosure Agreement will be required to receive copies of 
unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

A New Class of Immunomodulatory Drugs for Multiple Sclerosis

    Description of Technology: Multiple sclerosis (MS) is an autoimmune 
disease caused by activated autoimmune T lymphocytes in patients 
resulting in inflammatory demyelination in the central nervous system. 
Current treatments are focused on functional control of these activated 
autoimmune T cells, but these treatments are non-specific T cell 
inhibitors and have serious, sometimes fatal side effects. A specific 
therapy aimed at eliminating these autoimmune T cells through 
restimulation-induced cell death (RICD) could cure the disease and 
overcome the fatal side effects of current therapies.

[[Page 48320]]

NIAID inventors have identified a multi-valent tolerogen (MMPt), which 
can specifically elicit RICD of the activated, disease causing 
autoimmune T cells without compromising the general T cell-dependent 
immunity in the host. Animal studies have demonstrated that MMPt exerts 
robust therapeutic effects on both monophasic as well as relapsing-
remitting type of the disease, indicating its medical applicability for 
treating MS patients with active disease. NIAID is seeking partners to 
develop this multi-valent peptide to improve its efficacy for use in 
clinical trials.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.

    Potential Commercial Applications:

 Therapeutics

    Competitive Advantages:

 Tolerogen induced elimination of activated autoimmune T cells 
will overcome the fatal side effects of current therapies
 Treatment of all types of MS patients

    Development Stage:

 Preclinical (In vitro and in vivo animal studies)

    Inventors: Dr. Michael J. Lenardo (NIAID), Dr. Lixin Zheng (NIAID), 
Dr. Jian Li (NIAID), Dr. Jae Lee (NIAID), and Dr. Wei Lu (NIAID).
    Intellectual Property: HHS Reference No. E-064-2015, U.S. 
Provisional Patent Application Numbers: 62/130,285 filed March 9, 2015 
and 62/219,851 filed September 17, 2015, and US PCT application PCT/
US2016/021571 filed on March 9, 2016. Entered National Stage filing in 
US, EU, Canada, and Australia.
    Licensing Contact: Yogikala Prabhu, Ph.D., 301-761-7789; 
[email protected].
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize the MMPt peptide to improve its 
efficacy for use in clinical trials.
    For collaboration opportunities, please contact Yogikala Prabhu, 
Ph.D., 301-761-7789; [email protected].

    Dated: September 18, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2018-20664 Filed 9-21-18; 8:45 am]
 BILLING CODE 4140-01-P